RetinaCME
VIDEOCMEABO MOC

Therapeutic Targeting of the Complement System in Geographic Atrophy

Author(s)/Faculty: Judy E. Kim, MD; Michael S. Ip, MD
Release Date: 6/25/2021Expiration Date: 6/24/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0.75
Content Type: VideoProvider:
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) resulting in progressive and irreversible loss of visual function. Currently, there are no Food and Drug Administration-approved therapies for the treatment of GA but AREDS supplements are recommended for patients who are at risk of progressing to advanced AMD. Studies have demonstrated genetic variants of several complement factor genes as risk factors for AMD identifying the complement pathway as an attractive therapeutic target. Therapies that target the complement pathway are currently under clinical review and being assessed for their potential to delay progression of GA and improve GA outcomes. In this CME activity, experts in the field will examine the role of complement in AMD and assess the clinical efficacy of emerging approaches that target the complement cascade for the treatment of GA secondary to AMD.